Editorial
Therapeutic Options in the Management of Chronic Heart Failure Is There a Drug of First Choice? Milton Packer, MD From the basic error that specific remedies were created for particular diseases came the incorrect notion that the whole course of a disease, or even its separate stages, could be annihilated by a single remedy.
-Rudolf Virchow
Where there is no treatment, there are many treatments. Anonymous or over 30 years, the combined use of digitalis and diuretics has been the initial ap-L proach to the management of patients with chronic heart failure. These drugs achieved dominance in the treatment of this disorder not because we had compelling evidence for their efficacy and safety but because physicians had few therapeutic alternatives. If digitalis and mercurials failed to relieve symptoms in the 1950s, physicians were advised to try cathartics, cationic exchange resins, thyroidectomy, or vena caval ligation. 1 During the last decade, however, we have witnessed the emergence of many novel pharmacological approaches to the treatment of chronic heart failure. During the period of 1978-1988, new drugs have been developed and tested (orally or intravenously) in patients with heart failure at a rate of one new agent each month. Virtually all of these new drugs have produced hemodynamic benefits in some patients; a few have proved worthwhile during long-term treatment.
What is the place of these new drugs in the treatment of chronic heart failure? Until recently, most physicians reserved these drugs for patients with refractory symptoms who had failed therapy with conventional agents. This practice followed naturally from the fact that when most of these new drugs were tested in experimental protocols, they were first administered to the patients with the most advanced disease. Given their severe degree of disability, such patients seemed to have the most to gain if the treatment proved successful; given their poor prognosis, such patients seemed to have the least to lose if the new drug proved harmful. This approach, although rational, may not have produced the most optimal results. Patients with the most advanced disease may be particularly resistant to the pharmacological actions of some drugs (e.g., ,3-agonists and phosphodiesterase inhibitors)2'3 and susceptible to the adverse effects of others (e.g., converting enzyme inhibitors and calcium channel blockers).4-6 Furthermore, an effective drug might be especially advantageous if it were administered early in the syndrome so that its benefits could be experienced for longer periods of time. As a result, many clinicians have begun to prescribe the new drugs for heart failure earlier than ever beforesometimes before using traditional agents. Is this approach reasonable? In the past, we questioned the validity of using these new drugs at all; now we argue about when to use them and which agent to use first.
During the last 10 years, many drugs have been proposed as first-line agents in the treatment of chronic heart failure. Many physicians still favor the use of digitalis and diuretics.7 Others have proposed that converting-enzyme inhibitors, 13adrenergic agonists, and phosphodiesterase inhibitors be used'before the cardiac glycosides in most patients.8-10 Still others have suggested that the ,3-adrenergic blockers and calcium channel blockers might interfere with a deleterious pathophysiological process and should be used early to retard progression of the disease."12 All of these proposals have emerged at a time when the efficacy and safety of digitalis and diuretics have been questioned. 8, 9, should the clinician do?
How Do We Select a First-Line Drug for Heart Failure? Before evaluating the claims that have been made for various drugs in the treatment of chronic heart failure, we should specify the criteria that a new agent should fulfill before it can be considered a first-line drug.
The Drug Should Provide Rapid Relief of Symptoms
In the patient who is being seen by the physician for the first time and who has never previously received a drug for heart failure, it is essential to begin treatment with an agent that can provide rapid relief of the presenting symptoms (e.g., dyspnea or edema). Agents that require weeks or months to achieve their therapeutic effects fail to accomplish this goal.
The Drug Should Reduce Mortality
The effect of a new drug on survival is a principal factor that determines its place in therapy. If a new drug relieves symptoms and reduces mortality, then it would be used early in the disease in all patients who might benefit because any delay in the institution of treatment could cost lives. If the new drug improves symptoms but does not affect survival, then it might reasonably be reserved until patients experience symptoms that persist despite optimal treatment with a first-line agent. Finally, if the new drug reduces symptoms but increases mortality, then it would probably be abandoned or used only as a last-resort drug in patients in the terminal stages of heart failure.
The Drug Should Change the Natural History of the Disease
In a patient who has recently sustained an insult to the myocardium, every effort should be made to reverse the injury to the heart (if possible) and to prevent further loss of viable myocardium. Any drug that could achieve this goal should be administered early to reduce the risk of progression of the underlying disease. We might expect the resulting beneficial effect on ventricular function to be translated into a reduction in mortality or at least in morbidity (e.g., reduced medication requirements or number of hospitalizations). This goal is not identical to that of reducing mortality, however, because some drugs (e.g., those that prevent sudden death) may prolong life in chronic heart failure without favorably affecting ventricular performance or long-term functional capacity. The Drug Should Be Safe and Well Tolerated A first-line drug must have an excellent record of safety because it is difficult to give preference to a drug with important adverse effects and delay the use of an agent that is better tolerated. Whenever there are concerns about the frequency or seriousness of side effects, physicians generally reserve the new agent for the patient with the most advanced disease who has failed to respond to safer agents. It is this definition of "first-line" that has generally been used by regulatory agencies such as the Food and Drug Administration. First-line agents are distinguished from second-line agents more by their comparative safety than by their comparative efficacy. Assuming it is effective, any well-tolerated drug can become a first-line agent for the treatment of a cardiovascular condition; a drug is reserved for later use if there are concerns about its safety.
It should be emphasized that the selection of a first-line drug for the treatment of chronic heart failure is not synonymous with the selection of a drug for the patient with mild-to-moderate heart failure. The last term refers to the degree of exercise intolerance experienced by the patient but tells us little about how long such symptoms have been present or how the patient should be treated. Mild heart failure is not the same as early heart failure. To assume the two terms are identical is to assume (incorrectly) that ventricular dysfunction progresses predictably over time and that such progression is paralleled by worsening symptoms of heart failure. 16 Symptoms may be disabling early in the disease but become less severe over time (because of the effective use of endogenous compensatory mechanisms or because of a favorable response to therapy). Mild symptoms can become suddenly severe without a change in left ventricular function (when atrial tachyarrhythmias occur or in cases of dietary indiscretion). These concepts may explain why a patient's functional status does not appear to be an important determinant of the response to any drug for the treatment of chronic heart failure; effective drugs seem to work whether the symptoms are mild, moderate, or severe. Moreover, the goals of therapy in chronic heart failure (i.e., to reduce disability and prolong life) are the same regardless of the severity of symptoms, although the relative emphasis placed on these two goals may differ in different functional subsets. In the patient with minimal symptoms, the reduction of long-term cardiovascular morbidity and mortality would carry the highest priority, whereas in the patient with marked disability, the rapid and pronounced relief of symptoms would be of greatest importance. Which Drugs Can Be Considered First-Line Agents? Is there a drug that fulfills all of the criteria of a first-line agent in the treatment of chronic heart failure? To address this question, we need to evaluate the results of placebo-controlled, randomized, double-blind clinical trials.
Diuretics
Diuretics produce symptomatic benefits in patients with mild, moderate, and severe heart failure more rapidly than any other oral agent. Diuretics can relieve dyspnea and edema within hours or days, whereas the effects of digitalis, converting enzyme inhibitors, or fl-blockers may take weeks or months to become apparent.17,18 Therefore, as initial therapy for the patient who presents with worsening symptoms, diuretics fulfill an important criterion of a first-line drug.
After the symptoms of pulmonary and systemic congestion have been relieved, can diuretic therapy be withdrawn and an alternative drug (e.g., digitalis or a converting-enzyme inhibitor) be used as a first-line agent? One controlled study observed worsening of symptoms when captopril was substituted for diuretic therapy in patients with a history of pulmonary congestion.19 On the other hand, diuretics alone seem unable to maintain the stability of patients with heart failure for long periods of time.8 A high proportion of patients whose symptoms are well-controlled during their initial visit deteriorate clinically during the succeeding months when managed with diuretics alone; the risk of decompensation is reduced, however, when diuretics are combined with digitalis or a converting-enzyme inhibitor. 8 These observations suggest that diuretics are a necessary part of the treatment of most patients with heart failure but that diuretics alone do not provide optimal long-term control of this disease.
Are diuretics safe enough to be considered firstline drugs? There are concerns that the ability of diuretics to activate neurohormonal systems and deplete critical electrolytes may exacerbate ventricular arrhythmias in some patients.20 Could such deleterious effects (if left unblocked) adversely affect survival in chronic heart failure? This question cannot be reasonably investigated at present because most patients with heart failure cannot tolerate the long-term withdrawal of diuretic drugs. Yet, some caution seems warranted. Although diuretics may be necessary in nearly all patients, physicians might be well advised (once edema is relieved) to not use further increments in the dose of diuretics in an attempt to control the symptoms of heart failure with a single agent. Combined drug therapy may achieve greater long-term symptomatic benefits and fewer adverse neurohormonal and metabolic effects.8'2',22
Digitalis
Although some investigators have raised doubts about the efficacy and safety of digitalis,13-1'several controlled trials have now convincingly shown that the drug is an effective agent in the treatment of patients with chronic heart failure in normal sinus rhythm.8"10'23'24 In patients with moderate-to-severe symptoms, digoxin relieves disability and improves exercise tolerance.10,23 Even in patients whose symptoms are well controlled with diuretics, the addition of digoxin enhances ventricular performance and reduces the number of hospital visits for worsening heart failure and the need for high doses of furosemide. 8, 24 In patients already receiving digoxin, withdrawal of the drug is predictably accompanied by clinical deterioration,80'23 which may not be prevented by the addition of other therapeutic agents.'o Finally, contrary to conventional wisdom, digitalis seems to be well tolerated by most patients with heart failure; in controlled studies, adverse effects occurred less frequently with digoxin than with other drugs.8 "' Based on these observations, digoxin would appear to play an important role in any initial approach to the treatment of chronic heart failure.
Can digoxin be used alone in the management of these patients? Although the digitalis glycosides increase urinary sodium excretion, these effects are slow in onset and modest in magnitude when compared with diuretic drugs, and, thus, for the highly symptomatic patient, it is difficult to use digoxin alone as the initial approach to therapy. Furthermore, the effect of digitalis on the survival of patients with chronic heart failure remains unknown, and, thus, digoxin should be prescribed together with some drug or drug combination that can reduce mortality.
Converting-Enzyme Inhibitors
The converting-enzyme inhibitors are the only drugs used in the treatment of chronic heart failure that have been shown to both improve symptoms and prolong life. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 22, 23, [25] [26] [27] In addition, these drugs may attenuate the progressive left ventricular enlargement that is seen in patients who have recently sustained a large myocardial injury. 28, 29 These unique characteristics support the use of captopril or enalapril as a first-line drug in all patients with heart failure, regardless of the severity of symptoms. The ability of these agents to reduce mortality suggests that treatment with a convertingenzyme inhibitor should not be delayed until late in the disease process, because some patients without severe symptoms who may die during follow-up might otherwise have had their lives prolonged by earlier intervention. Finally, most patients (except for those with the most advanced disease4,5) tolerate therapy with converting-enzyme inhibitors well. Although dizziness remains a frequent complaint, few patients need to discontinue treatment because of adverse effects. 8 Can converting-enzyme inhibitors be used alone in the management of chronic heart failure? Every trial that has demonstrated a favorable effect of captopril and enalapril on symptoms and survival has enrolled patients who were treated concurrently with diuretics.8'17 '21,22,25-27 Converting-enzyme inhibitors cannot control the symptoms of most patients with heart failure in the absence of diuretic therapy,' 9 possibly because the hemodynamic and clinical effects of captopril and enalapril are attenuated in patients with an increased total body sodium content or with markedly elevated central venous pressures.30'3' These observations suggest that diuretics modify the neurohormonal milieu (by stimulating the renin-angiotensin system) so as to sensitize the circulation to the actions of a convertingenzyme inhibitor.3' Captopril and enalapril can, in turn, reduce the loss of electrolytes, the activation of neurohormones, and the ventricular arrhythmias that may be caused by diuretic therapy.20-22 Any therapeutic approach to heart failure that relies on only one of these agents fails to take advantage of such complementary actions.
Direct-Acting Vasodilators
A combination of hydralazine and isosorbide dinitrate has been reported to reduce mortality in patients with chronic heart failure in one large, multicenter study. 32 This finding suggests that one or both of these vasodilator drugs may alter the natural history of the disease33-an important criterion of a first-line agent.
However, this vasodilator combination produces only modest and inconsistent symptomatic benefits in patients with chronic heart failure,34'35 and longterm therapy is accompanied by high incidence of adverse reactions, which frequently necessitate the discontinuation of one or both drugs. 32 The converting-enzyme inhibitors, on the other hand, may produce greater relief of symptoms and fewer side effects. 25, 26, 32, 36 Whereas captopril and enalapril prolong life even in patients treated with directacting vasodilators and may do so more effectively than hydralazine alone,25,37 we do not know whether direct-acting vasodilators add to the beneficial effects of converting-enzyme inhibitors on symptoms or survival. These observations provide little reason to use hydralazine and isosorbide dinitrate before or in concert with the converting-enzyme inhibitors in patients with chronic heart failure and, thus, do not support the use of this drug combination as a first-line approach in the treatment of this disease. a-Adrenergic antagonists (such as prazosin) produce neither symptomatic nor prognostic benefits in heart failure and are inferior in efficacy to other vasodilator drugs.32'38'39 Thus, they are not to be considered first-line agents in these patients.
Calcium Channel Blocking Drugs
Calcium channel blocking drugs have not been shown to produce clinical benefits in chronic heart failure and appear to be less effective than other vasodilator drugs (e.g., converting-enzyme inhibitors) in the treatment of this condition.40 Calcium channel blockers can also produce important negative inotropic effects in many patients, which may be accompanied by worsening symptoms of heart failure.6'41 This risk appears to be greatest in patients in the late stages of their illness. 6 Because of the disadvantages of these drugs in patients with advanced disease, interest has focused on the early use of calcium channel blockers to prevent the development of heart failure in patients with a recent myocardial injury. Under experimental conditions, the progression of mild to severe left ventricular dysfunction has been ascribed to the occurrence of ischemic necrosis secondary to microvascular spasm42 or to overload of the cardiac cell by calcium.43 Both microvascular spasm and calcium overload may be inhibited by treatment with a calcium channel blocker, however, and agents such as verapamil have been shown to prevent the development of experimental cardiomyopathy.'2'44 Based on these concepts, calcium channel blockers have been recommended as first-line agents in patients with early left ventricular dysfunction to minimize any further loss of viable myocardium. 12 No clinical studies are available to support this hypothesis, however, and recent observations have raised concerns that early therapy with calcium channel blockers in patients with recentonset heart failure may enhance rather than diminish morbidity and mortality.45
Phosphodiesterase Inhibitors
The initial reports of the use of the phosphodiesterase inhibitors in chronic heart failure suggested that these agents had considerable promise as firstline agents.46 These drugs exert both positive inotropic and peripheral vasodilator effects and, thus, act to correct the two principal hemodynamic abnormalities (depressed contractility and excessive vasoconstriction) seen in these patients. The ability of the phosphodiesterase inhibitors to increase cardiac contractility, however, is dependent on the content of cyclic AMP within the myocardial cell, which declines as the heart failure state progresses in severity over time. 47 Patients with the most advanced disease may therefore be particularly resistant to the cardiostimulatory effects of these drugs.2'47 As a result, some investigators have suggested that the phosphodiesterase inhibitors should be used early in the disease, perhaps as a substitute for digitalis.1'
Most of the large-scale clinical trials that have been conducted to date with the phosphodiesterase inhibitors (amrinone, milrinone, enoximone, or imazodan), however, have not been able to show that these drugs can relieve the symptoms of patients with chronic heart failure who are treated with digitalis and diuretics. 10'48-51 Attempts to investigate the possibility that these drugs could be substituted for digitalis as a first-line agent have met with similarly disappointing results. In one double-blind controlled trial, milrinone failed to prevent the clinical deterioration that followed the withdrawal of digoxin. 10, 5 Furthermore, patients treated with milrinone had more frequent ventricular arrhythmias and showed more rapid progression of their disease than patients treated with digoxin.10'50'51 These observations have raised concerns that the phosphodiesterase inhibitors might exert a deleterious effect on the survival of patients with chronic heart failure. 52 The paucity of data showing efficacy, coupled with concerns about safety, has reduced the enthusiasm for these drugs as potential first-line agents.
f3-Adrenergic Antagonists
,B-Blockers have particular appeal as possible first-line drugs in the treatment of chronic heart failure because they interfere with the potentially deleterious effects of prolonged adrenergic stimulation on the failing heart and, thus, like calcium channel blockers, may interrupt an important pathophysiological mechanism that may contribute to disease progression.'1 Unlike the calcium channel blockers, however, /3-blockers have been shown to produce long-term hemodynamic and symptomatic benefits in some patients with a dilated cardiomyopathy.'1853 Unlike the calcium channel blockers, (3-blockers can favorably influence the survival of patients with left ventricular dysfunction after acute myocardial infarction, in whom treatment is initiated shortly after the onset of myocardial injury.54 Hence, the /3-blockers could potentially fulfill many of the criteria of a first-line agent for chronic heart failure because (like convertingenzyme inhibitors) they may act to both improve symptoms and prolong life.18,55 These observations, although encouraging, must be viewed with caution because experience with these drugs remains limited.
For most physicians, however, concern about safety remains the major obstacle to the use of /3-blockers as first-line agents in chronic heart failure. In published reports, 5-20% of patients deteriorated clinically during initiation of therapy with these drugs; this risk was significant even in patients treated early in the disease.'8.54-56 Some investigators have suggested that this complication can be avoided by incorporating l3-agonist activity into the pharmacological profile of the /3-blocking drug, and preliminary trials with such an agent (xamoterol) have been encouraging.9 Yet, the long-term efficacy and safety of drugs that stimulate the l3-receptor remain unknown. /3-Adrenergic agonists have not been shown to improve symptoms in chronic heart failure.57,58 and some investigators fear that longterm treatment with these agents could enhance mortality.52.59,6t' The presence of intrinsic agonist activity could potentially abolish the ability of /3blocking drugs to prolong survival.60t 6x Additional data concerning the effects of /3-adrenergic agonists and antagonists on mortality in chronic heart failure are needed before we can adequately define the role of these drugs as first-line agents.
Conclusion
Three classes of drugs (diuretics, digitalis, and converting-enzyme inhibitors) each fulfill some of the criteria of a first-line agent in the treatment of chronic heart failure. Yet, none of these drugs satisfies all of the desired characteristics, and none can optimally manage the heart failure state when used alone. Diuretic drugs control fluid retention, but they cannot maintain clinical stability in symptomatic patients. Digoxin reduces long-term cardiovascular morbidity in chronic heart failure, but the effect of this drug on mortality remains unknown. Converting-enzyme inhibitors decrease both morbidity and mortality in this disorder, but they cannot prevent fluid retention. Hence, there would appear to be many first-line drugs in the treatment of chronic heart failure, and the complementary actions of these agents should always be combined in an effort to improve symptoms and prolong life. It therefore seems logical that no patient with chronic heart failure should be treated with a single drug.
Should all of the first-line drugs be prescribed the first time the patient with chronic heart failure is seen by the physician? Therapy with diuretics should be used initially to rapidly control symptoms of pulmonary congestion and to relieve edema. Additional first-line drugs might be best temporarily withheld until this rapid diuretic phase has been completed. Premature institution of therapy with digitalis could increase the risk of digitalis toxicity if the diuresis has produced important potassium deficits. Similarly, premature institution of therapy with a converting-enzyme inhibitor could cause symptomatic hypotension if the diuresis has increased the circulation's dependency on angiotensin II.4 Either or both drugs can (and should be) safely started once steady-state conditions have been achieved-at a lower and less-symptomatic weight. This goal can generally be accomplished within 1-2 weeks after the acute symptoms of pulmonary and systemic congestion have subsided.
Future research should bring additional first-line drugs for heart failure to the medical community. Drugs are needed that will retard progression of the disease and will prevent sudden death. If such agents are developed (and are well tolerated), they will join the first-line drugs that are already available. The more agents that we can develop that can change the natural history of chronic heart failure, the more definitive and the less palliative the treatment of this disease will become.
